Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: Improving upon nature
- 1 September 2008
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 110 (3), S1-S10
- https://doi.org/10.1016/j.ygyno.2008.05.036
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting InfectionJAMA, 2007
- Chapter 2: The burden of HPV-related cancersVaccine, 2006
- Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical CancerCancer Epidemiology, Biomarkers & Prevention, 2005
- The epidemiology of human papillomavirus infectionsJournal of Clinical Virology, 2005
- Chapter 1: Human Papillomavirus and Cervical Cancer--Burden and Assessment of CausalityJNCI Monographs, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up studyBMJ, 2002
- Persistent Human Papillomavirus Infection as a Predictor of Cervical Intraepithelial NeoplasiaJAMA, 2001
- Type-Specific Persistence of Human Papillomavirus DNA before the Development of Invasive Cervical CancerNew England Journal of Medicine, 1999
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999